Earnings Conference Call Overview: American Healthcare REIT, Inc. held its Q2 2025 earnings conference call on August 8, 2025, featuring key executives discussing operational results, financial position, and updated guidance for the year.
Forward-Looking Statements: The call included forward-looking statements that are subject to risks and uncertainties, which could lead to actual results differing from projections.
AHR
$47.62+Infinity%1D
Analyst Views on AHR
Wall Street analysts forecast AHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AHR is 55.20 USD with a low forecast of 47.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast AHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AHR is 55.20 USD with a low forecast of 47.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 47.200
Low
47.00
Averages
55.20
High
60.00
Current: 47.200
Low
47.00
Averages
55.20
High
60.00
Truist
Buy
upgrade
$46 -> $53
2025-11-26
Reason
Truist
Price Target
$46 -> $53
2025-11-26
upgrade
Buy
Reason
Truist raised the firm's price target on American Healthcare REIT to $53 from $46 and keeps a Buy rating on the shares. The firm is raising its FFO estimates and price target following strong results and higher earnings guidance, the analyst tells investors in a research note. American Healthcare REIT appears very well positioned to benefit from favorable industry trends, the firm added.
Citi
Neutral
maintain
$45 -> $52
2025-11-21
Reason
Citi
Price Target
$45 -> $52
2025-11-21
maintain
Neutral
Reason
Citi raised the firm's price target on American Healthcare REIT to $52 from $45 and keeps a Neutral rating on the shares. The firm updated the company's model post the Q3 report.
Morgan Stanley
Overweight
maintain
$52 -> $55
2025-11-20
Reason
Morgan Stanley
Price Target
$52 -> $55
2025-11-20
maintain
Overweight
Reason
Morgan Stanley raised the firm's price target on American Healthcare REIT (AHR) to $55 from $52 and keeps an Overweight rating on the shares. After examining Q3 results as well as supply/demand fundamentals in senior housing, the firm says it has higher conviction in Welltower (WELL) and American Healthcare's ability to execute on margin upside.
UBS
Buy
maintain
$51 -> $56
2025-11-17
Reason
UBS
Price Target
$51 -> $56
2025-11-17
maintain
Buy
Reason
UBS raised the firm's price target on American Healthcare REIT to $56 from $51 and keeps a Buy rating on the shares.
About AHR
American Healthcare REIT, Inc. is a real estate investment trust that acquires, owns and operates a diversified portfolio of clinical healthcare real estate, focusing primarily on senior housing, skilled nursing facilities, outpatient medical (OM) buildings and other healthcare-related facilities across the United States, the United Kingdom and the Isle of Man. It owns and operates its integrated senior health campuses and senior housing operating properties (SHOP). Its segments include integrated senior health campuses, OM, SHOP and triple-net leased properties. Its OM buildings are leased to multiple tenants under separate leases. Its integrated senior health campuses each provide a range of independent living, assisted living, memory care, skilled nursing services and ancillary businesses. Its triple-net leased properties segment includes senior housing, skilled nursing facilities and hospitals. Its SHOP segment includes senior housing providing assisted living care, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
